What does a positive BCL‑6 (B‑cell lymphoma‑6) immunostain and CD138 (syndecan‑1) immunostain indicating endometriosis signify for a reproductive‑age woman undergoing surrogate evaluation, and how should I counsel her regarding management and eligibility?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 7, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Understanding BCL-6 and CD138 Immunostaining in Your Patient's Surrogate Evaluation

The positive BCL-6 and CD138 immunostains indicate your patient likely has endometrial dysfunction, most probably from occult endometriosis (96% positive predictive value), and this finding should prompt referral to a reproductive endocrinologist or endometriosis specialist before she proceeds with surrogacy—she is not currently cleared for embryo transfer.

What These Markers Actually Mean

BCL-6 (B-cell Lymphoma-6)

  • BCL-6 overexpression is a marker of progesterone resistance and endometrial dysfunction 1
  • In women with unexplained infertility, elevated BCL-6 has a 96% positive predictive value for surgically-confirmed endometriosis 2
  • The cutoff used is typically an H-score >1.4, which differentiates endometriosis cases from normal controls with 94% accuracy 1
  • BCL-6 is significantly elevated in the secretory phase endometrium of women with endometriosis compared to fertile controls 1

CD138 (Syndecan-1)

  • CD138 traditionally identifies plasma cells and is used to diagnose chronic endometritis 3, 4
  • However, recent high-quality evidence shows CD138 is constitutively expressed on glandular epithelial cells and stromal cells throughout the menstrual cycle 5
  • Stromal CD138 expression is cycle-dependent, very high in proliferative phase, and declines after ovulation 5
  • Critical caveat: CD138 positivity is associated with endometrial immaturity and impaired luteal phase timing, but NOT with altered microbiota composition 5

Clinical Implications for Surrogacy

Your patient should NOT proceed with surrogacy at this time. Here's the algorithmic approach:

Step 1: Confirm the Diagnosis

  • The combination of BCL-6 and CD138 positivity suggests both endometrial dysfunction from likely endometriosis AND possible chronic endometritis or endometrial timing issues 3
  • In one study, 71% of cases were positive for at least one of these markers (CD56, BCL-6, or CD138), and combined testing improved diagnostic yield 3

Step 2: Refer for Definitive Evaluation

Refer to a reproductive endocrinologist or endometriosis specialist for:

  • Diagnostic laparoscopy - Given the 96% PPV of BCL-6 for endometriosis, surgical diagnosis is warranted 2
  • In the 4% of BCL-6 positive cases without endometriosis, 100% had other inflammatory pelvic pathologies requiring treatment 2
  • Imaging may be appropriate first: transvaginal ultrasound or pelvic MRI can identify deep endometriosis and guide surgical planning 6

Step 3: Treatment Before Embryo Transfer

If endometriosis is confirmed:

  • Surgical excision by a specialist is the definitive treatment 6
  • Medical suppression (GnRH agonists, progestins) may be considered pre-transfer 7
  • Pregnancy rates improved from 58.5% to 73.8% after targeted therapy in BCL-6/CD138 positive cases 3

If chronic endometritis is confirmed:

  • Note that recent evidence questions the relationship between CD138+ cells and true bacterial chronic endometritis 5
  • CD138 positivity may reflect endometrial immaturity rather than infection 5
  • Antibiotic treatment for CE should not be performed outside research context per the most recent high-quality data 5

Key Counseling Points for Your Patient

Regarding Surrogacy Eligibility

  • She is currently NOT cleared - these findings indicate endometrial dysfunction that could compromise implantation
  • Surrogacy agencies and IVF programs require optimal endometrial receptivity
  • Treatment and clearance are needed before proceeding

Regarding Her Own Fertility

  • These findings suggest she may have occult endometriosis affecting her own fertility 1
  • If she has personal fertility goals, this should be addressed concurrently
  • Endometriosis affects approximately 10% of reproductive-age women and is associated with infertility in 50% of cases 6

Timeline Expectations

  • Diagnostic laparoscopy: 2-4 weeks for scheduling, 2-4 weeks recovery
  • If medical suppression is used: typically 3-6 months
  • Re-evaluation with repeat endometrial biopsy may be needed to confirm treatment response

Common Pitfalls to Avoid

  1. Don't dismiss these findings as "just markers" - BCL-6 has very high predictive value for surgically-significant pathology 2

  2. Don't empirically treat with antibiotics based solely on CD138 - the newest evidence shows CD138 is constitutively expressed and not necessarily infection-related 5

  3. Don't allow her to proceed with surrogacy without specialist evaluation - the surrogate agency sent her to you to "clear it up" but these findings indicate she needs subspecialty care, not clearance

  4. Don't confuse the markers: BCL-6 = endometriosis/progesterone resistance; CD138 = chronic endometritis OR endometrial timing dysfunction (the distinction matters for treatment) 3, 5

Your Immediate Action Plan

Tell the patient: "Your endometrial biopsy shows markers that strongly suggest you have endometriosis and possibly endometrial inflammation or timing issues. These findings mean your uterine lining may not be optimal for embryo implantation. You need evaluation by a fertility specialist or endometriosis surgeon before you can be cleared for surrogacy. This will likely involve imaging studies and possibly a diagnostic laparoscopy. Once treated, you can be re-evaluated for surrogacy eligibility."

Document in your note: "Patient presents with positive BCL-6 and CD138 immunostaining on endometrial biopsy performed for surrogate evaluation. Given 96% PPV of BCL-6 for endometriosis and implications for endometrial receptivity, patient is NOT cleared for surrogacy at this time. Referred to [reproductive endocrinology/endometriosis specialist] for diagnostic evaluation and treatment. Surrogate agency notified of need for specialist clearance."

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.